2cureX AB (publ) (2CUREX.ST)
SEK 0.4
(-5.24%)
SEK 0.4
(-5.24%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -36.36 Million SEK | -16.66% |
| 2022 | -32.13 Million SEK | -40.93% |
| 2021 | -22.8 Million SEK | -207.37% |
| 2020 | -7.41 Million SEK | 15.21% |
| 2019 | -8.74 Million SEK | -3.71% |
| 2018 | -8.43 Million SEK | -112.33% |
| 2017 | -3.97 Million SEK | -155.35% |
| 2016 | -1.55 Million SEK | -70.04% |
| 2015 | -915.03 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -4.81 Million SEK | 46.02% |
| 2024 Q2 | -4.81 Million SEK | 0.0% |
| 2023 Q2 | -8.68 Million SEK | -2.76% |
| 2023 FY | -37.48 Million SEK | -16.66% |
| 2023 Q4 | -8.91 Million SEK | 3.63% |
| 2023 Q3 | -9.24 Million SEK | -6.54% |
| 2023 Q1 | -8.44 Million SEK | -19.07% |
| 2022 Q2 | -7.54 Million SEK | 6.69% |
| 2022 FY | -32.13 Million SEK | -40.93% |
| 2022 Q4 | -7.09 Million SEK | 24.58% |
| 2022 Q3 | -9.4 Million SEK | -24.65% |
| 2022 Q1 | -8.08 Million SEK | -10.51% |
| 2021 Q3 | -6.55 Million SEK | -3.88% |
| 2021 Q2 | -6.31 Million SEK | -141.02% |
| 2021 Q1 | -2.61 Million SEK | -79.07% |
| 2021 FY | -22.8 Million SEK | -207.37% |
| 2021 Q4 | -7.31 Million SEK | -11.64% |
| 2020 Q3 | -1.1 Million SEK | 51.58% |
| 2020 Q2 | -2.28 Million SEK | 11.35% |
| 2020 FY | -7.41 Million SEK | 15.21% |
| 2020 Q4 | -1.46 Million SEK | -32.43% |
| 2020 Q1 | -2.57 Million SEK | -29.77% |
| 2019 FY | -8.74 Million SEK | -3.71% |
| 2019 Q1 | -1.76 Million SEK | -4.89% |
| 2019 Q3 | -2.02 Million SEK | 32.04% |
| 2019 Q4 | -1.98 Million SEK | 2.17% |
| 2019 Q2 | -2.98 Million SEK | -69.38% |
| 2018 Q1 | -2.94 Million SEK | 5.21% |
| 2018 FY | -8.43 Million SEK | -112.33% |
| 2018 Q3 | -715 Thousand SEK | 76.91% |
| 2018 Q2 | -3.09 Million SEK | -5.02% |
| 2018 Q4 | -1.67 Million SEK | -134.69% |
| 2017 Q4 | -3.1 Million SEK | -936.65% |
| 2017 FY | -3.97 Million SEK | -155.35% |
| 2017 Q1 | -1.54 Million SEK | -415.25% |
| 2017 Q2 | -1.23 Million SEK | 20.59% |
| 2017 Q3 | -300 Thousand SEK | 75.61% |
| 2016 FY | -1.55 Million SEK | -70.04% |
| 2016 Q4 | 491.35 Thousand SEK | 0.0% |
| 2015 FY | -915.03 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 85.395% |
| Ziccum AB (publ) | -21.56 Million SEK | -68.66% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -121.712% |
| BioArctic AB (publ) | 252.64 Million SEK | 114.393% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -4203.314% |
| Mendus AB (publ) | -100.65 Million SEK | 63.872% |
| Genovis AB (publ.) | 54.22 Million SEK | 167.061% |
| Intervacc AB (publ) | -93.57 Million SEK | 61.142% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -134.419% |
| Active Biotech AB (publ) | -46.48 Million SEK | 21.773% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 301.916% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 34.383% |
| Aptahem AB (publ) | -10.1 Million SEK | -259.86% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 88.69% |
| Kancera AB (publ) | -65.04 Million SEK | 44.093% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 72.988% |
| Fluicell AB (publ) | -26.87 Million SEK | -35.284% |
| Saniona AB (publ) | -81.06 Million SEK | 55.143% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -193.937% |
| Biovica International AB (publ) | -126.07 Million SEK | 71.157% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 14.45% |
| AcouSort AB (publ) | -17.48 Million SEK | -107.943% |
| Xintela AB (publ) | -57.23 Million SEK | 36.471% |
| Abliva AB (publ) | -96.54 Million SEK | 62.337% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 88.804% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -937.461% |
| OncoZenge AB (publ) | -15.9 Million SEK | -128.669% |
| Amniotics AB (publ) | -29.07 Million SEK | -25.075% |
| CombiGene AB (publ) | -36.3 Million SEK | -0.159% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -148.381% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 90.54% |
| Camurus AB (publ) | 532.35 Million SEK | 106.831% |
| Corline Biomedical AB | -1.78 Million SEK | -1933.725% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 79.884% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 12.763% |
| I-Tech AB | 24.43 Million SEK | 248.815% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 95.388% |
| Cyxone AB (publ) | -21.66 Million SEK | -67.873% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 65.684% |
| Biosergen AB | -27.26 Million SEK | -33.369% |
| Cantargia AB (publ) | -290.01 Million SEK | 87.462% |
| NextCell Pharma AB | -43.17 Million SEK | 15.772% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 79.884% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -112.695% |
| Nanologica AB (publ) | -69.96 Million SEK | 48.025% |
| SynAct Pharma AB | -224.49 Million SEK | 83.802% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 17.686% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -51.802% |
| LIDDS AB (publ) | -40.67 Million SEK | 10.599% |
| Lipum AB (publ) | -37.25 Million SEK | 2.392% |
| BioInvent International AB (publ) | -369.94 Million SEK | 90.171% |
| Alzinova AB (publ) | -16.52 Million SEK | -120.088% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 85.653% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -468.772% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 68.4% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -80.56% |
| Simris Alg AB (publ) | -36.63 Million SEK | 0.742% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 75.19% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 88.286% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 67.215% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -214.396% |